SCHEMBL1689969

SCHEMBL1689969

Oc1cc(I)cc(-c2ccsc2)c1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 6/20 0.42
CYP2B6 P20813 3/20 0.42
CYP2E1 P05181 2/20 0.42
ERN1 O75460 5/20 0.41
ACMSD Q8TDX5 1/20 0.41
PELI1 Q96FA3 2/20 0.41
KCNH2 Q12809 1/20 0.40
GLO1 Q04760 1/20 0.37
CYP17A1 P05093 1/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
ABL1 P00519 1/20 0.35
ABCB1 P08183 1/20 0.35
BCR P11274 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6067952 0.86 CYP2A6 (0.50) CYP2A6CYP2B6CYP2E1ERN1ACMSD
SCHEMBL21944782 0.77 ERN1 (0.45) CYP2A6CYP2B6CYP2E1ERN1ACMSD
SCHEMBL21944861 0.77 ERN1 (0.49) CYP2A6CYP2B6CYP2E1ERN1ACMSD
SCHEMBL1689638 0.73 PDGFRB (0.47) CYP2A6CYP2B6CYP2E1ERN1KCNH2
SCHEMBL4442916 0.72 HSD17B1 (0.58) CYP2A6CYP2B6CYP2E1ERN1ACMSD
SCHEMBL2125063 0.71 CYP2A6 (0.72) CYP2A6CYP2B6CYP2E1ERN1ACMSD
SCHEMBL7448864 0.70 CYP2A6 (0.58) CYP2A6CYP2B6CYP2E1ERN1ACMSD
SCHEMBL649500 0.70 CYP2A6 (0.58) CYP2A6CYP2B6CYP2E1ERN1ACMSD
SCHEMBL21944869 0.69 GAK (0.43) CYP2A6ERN1PELI1
SCHEMBL21945438 0.69 GAK (0.43) CYP2A6CYP2B6CYP2E1ERN1ACMSD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093385-B2 Leukotriene B4 inhibitors HOFFMANN-LA ROCHE INC. (US) 2012-01-10 US disclosed
US-8093385-B2 Leukotriene B4 inhibitors HOFFMANN-LA ROCHE INC. (US) 2012-01-10 US disclosed
US-8093385-B2 Leukotriene B4 inhibitors HOFFMANN-LA ROCHE INC. (US) 2012-01-10 US disclosed
CN-101821226-A Leukotriene b4 inhibitors HOFFMANN LA ROCHE 2010-09-01 CN disclosed
EP-2190808-A1 LEUKOTRIENE B4 INHIBITORS F. Hoffmann-Roche AG (CH) 2010-06-02 EP disclosed
WO-2009024492-A1 LEUKOTRIENE B4 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-02-26 WO disclosed
US-20090054466-A1 Leukotriene B4 Inhibitors DOMINIQUE ROMYR 2009-02-26 US disclosed
US-20090054466-A1 Leukotriene B4 Inhibitors DOMINIQUE ROMYR 2009-02-26 US disclosed
US-20090054466-A1 Leukotriene B4 Inhibitors DOMINIQUE ROMYR 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054466-A1 Leukotriene B4 Inhibitors LTB4R2, LTB4R, LTC4S CYP2A6 300/4885CYP2B6 116/4885CYP2E1 474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.